Glucagon-like peptide-1 (GLP-1) receptor agonists, including semaglutide (brand names Ozempic and Wegovy) and tirzepatide (brand name Mounjaro), are medications used to treat type 2 diabetes and obesity.
October 10, 2025
high
temporal
Baseline description of the drug class and common brand examples.
GLP-1 receptor agonist medications (examples include semaglutide marketed as Ozempic and Wegovy, tirzepatide marketed as Mounjaro, and other agents such as Zepbound) mimic the gut hormone glucagon-like peptide-1 (GLP-1) and act by slowing digestion, reducing appetite, and helping to control blood sugar after meals.
January 01, 2025
high
descriptive
Mechanism of action and metabolic effects of GLP-1 receptor agonist medications used for weight loss and glycemic control.
GLP-1 medications commonly referenced for diabetes and weight loss include semaglutide and tirzepatide.
high
clinical
GLP-1 is a drug class used to treat diabetes and for weight-loss therapies.
Unregulated or compounded versions of prescription peptides such as semaglutide can contain unverified chemical forms that differ from FDA‑approved formulations, creating safety and quality concerns.
high
safety
Compounded or unregulated peptide products may not match approved chemical specifications and can pose risks.
GLP-1 receptor agonist medications (examples include semaglutide, liraglutide, and tirzepatide) mimic endogenous hormones that help regulate blood sugar and appetite.
high
general
Pharmacologic description of the GLP-1 receptor agonist drug class.
GLP-1 drugs, including semaglutide formulations marketed as Ozempic and Wegovy, are used both for weight loss and for treatment of type 2 diabetes.
high
descriptive
Therapeutic uses of GLP-1 receptor agonist medications.